Sebia, Inc.

Sebia, Inc., headquartered in Norcross, Georgia, manufactures and supplies automated electrophoresis analyzers, reagents, consumables, and clinical laboratory testing services exclusively to federal agencies as a prime contractor, with no subcontracting activity. The company competes full-and-open across its federal portfolio with no set-aside designations, and operates as a specialized supplier of proprietary diagnostic equipment and in-vitro testing solutions under primary NAICS 325413 (Laboratory Equipment and Supplies) and PSC 6640 (Laboratory Equipment and Supplies).

Sebia's capability footprint centers on capillary electrophoresis systems—primarily Capillarys and Hydrasys analyzers—and related reagents, controls, and clinical testing services for protein analysis, hemoglobin A1c determination, immunofixation testing, and carbohydrate-deficient transferrin analysis. Representative work includes a $4.47 million single-award indefinite-delivery contract with the Defense Health Agency for electrophoresis testing equipment and reagents at San Antonio Military Medical Center through September 30, 2028; a $4.23 million indefinite-delivery contract with Department of Veterans Affairs Veterans Integrated Service Network 22 for electrophoresis instruments, supplies, installation, and training across Southwest VA facilities through February 28, 2027; a $3.56 million single-award indefinite-delivery contract with VISN 8 for cost-per-test electrophoresis services to Florida and Caribbean VA facilities through April 30, 2031; and a $32 million Federal Supply Schedule contract (Critical Analyzers, Laboratory FSS-66-III) with the Department of Veterans Affairs. Recent delivery orders include a $380,120 firm fixed-price call from VISN 8 for electrophoresis equipment (May 2026), a $479,235 delivery order from VISN 22 for electrophoresis products (April 2025), and a $1.13 million firm fixed-price purchase order from the Defense Health Agency for Capillarys 3 Octa reagents and supplies at Madigan Army Medical Center through September 2028.

Customer concentration anchors heavily with the Department of Veterans Affairs and its regional networks. The top five funding entities account for approximately 67% of combined potential value, led by VA VISN 12 (34 awards, $43.8 million), followed by VA VISN 22 (88 awards, $14.9 million), VA VISN 8 (60 awards, $14.2 million), the Defense Health Agency (23 awards, $7.9 million), and the Department of the Army Medical Command (49 awards, $6.4 million). Award count and dollar concentration diverge notably—VISN 22 and VISN 8 place numerous smaller orders, while VISN 12 anchors the portfolio with high-value delivery orders for cost-per-test clinical pathology services. Sebia serves 30 distinct federal customer agencies, but approximately 86% of activity channels through VA networks and military medical commands.

Sebia places the overwhelming majority of task orders and delivery orders under the Critical Analyzers, Laboratory Federal Supply Schedule (420 task orders, $35.1 million combined potential value), which serves as the parent vehicle for the majority of VA network procurements. The company also holds multiple single-award indefinite-delivery contracts with individual VA networks and the Defense Health Agency, enabling cost-per-test and reagent-rental business models. Federal Supply Schedule V797P4103A carries 174 task orders valued at $1.5 million. These vehicles establish Sebia as the de facto incumbent for electrophoresis testing across the VA system.

Activity has grown modestly year-over-year, from 23 awards in 2022 to a peak of 41 in 2024, with 36 awards in 2025 and 14 in the first half of 2026. A total of 1,147 awards across the source data window carry a combined potential value of $130 million, with $38.4 million obligated (30% draw). Twenty-six awards (combined potential value $3.6 million) reach ultimate completion within the next twenty-four months, representing moderate recompete exposure concentrated in routine VISN renewal cycles and Defense Health Agency reagent contracts.

Sebia operates exclusively as a prime contractor with no subcontracting footprint. The company's revenue model is characterized by recurring delivery orders and task calls under standing IDIQs and BPAs, delivering reagents, consumables, and occasional equipment purchases rather than large system implementations. Awards across 2024–2026 reflect sustained demand for electrophoresis testing capabilities within federal healthcare laboratories, where Sebia's proprietary analyzer technology and compatibility with existing PHORESIS laboratory information systems create switching costs and support sole-source and competitive 8(a) awards at VA VISN 15 and other networks. The company's strategic positioning as the original equipment manufacturer for Capillarys and Hydrasys systems anchors its federal customer base across two decades of established relationships with the Veterans Health Administration and military medical treatment facilities.